194 related articles for article (PubMed ID: 17049678)
1. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides.
Inoue J; Aramaki Y
Vaccine; 2007 Jan; 25(6):1007-13. PubMed ID: 17049678
[TBL] [Abstract][Full Text] [Related]
2. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in mice.
Inoue J; Yotsumoto S; Sakamoto T; Tsuchiya S; Aramaki Y
J Control Release; 2005 Nov; 108(2-3):294-305. PubMed ID: 16209897
[TBL] [Abstract][Full Text] [Related]
3. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy.
Kigasawa K; Kajimoto K; Nakamura T; Hama S; Kanamura K; Harashima H; Kogure K
J Control Release; 2011 Mar; 150(3):256-65. PubMed ID: 21256903
[TBL] [Abstract][Full Text] [Related]
5. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
6. Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-alpha signaling.
Lim EJ; Lee SH; Lee JG; Chin BR; Bae YS; Kim JR; Lee CH; Baek SH
FEBS Lett; 2006 Aug; 580(18):4533-8. PubMed ID: 16870179
[TBL] [Abstract][Full Text] [Related]
7. Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration.
von Beust BR; Johansen P; Smith KA; Bot A; Storni T; Kündig TM
Eur J Immunol; 2005 Jun; 35(6):1869-76. PubMed ID: 15909311
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
[TBL] [Abstract][Full Text] [Related]
9. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
[TBL] [Abstract][Full Text] [Related]
10. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation.
Rattanakiat S; Nishikawa M; Takakura Y
Eur J Pharm Sci; 2012 Sep; 47(2):352-8. PubMed ID: 22771546
[TBL] [Abstract][Full Text] [Related]
11. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in NC/Nga mice.
Inoue J; Yotsumoto S; Sakamoto T; Tsuchiya S; Aramaki Y
Pharm Res; 2005 Oct; 22(10):1627-33. PubMed ID: 16180119
[TBL] [Abstract][Full Text] [Related]
12. Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen.
Mutwiri G; Benjamin P; Soita H; Babiuk LA
Vaccine; 2008 May; 26(22):2680-8. PubMed ID: 18430493
[TBL] [Abstract][Full Text] [Related]
13. Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism.
Anderson RB; Cianciolo GJ; Kennedy MN; Pizzo SV
J Leukoc Biol; 2008 Feb; 83(2):381-92. PubMed ID: 17967834
[TBL] [Abstract][Full Text] [Related]
14. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
15. Contribution of human neutrophils in the development of protective immune response during in vitro Leishmania major infection.
Safaiyan S; Bolhassani A; Nylen S; Akuffo H; Rafati S
Parasite Immunol; 2011 Nov; 33(11):609-20. PubMed ID: 21793857
[TBL] [Abstract][Full Text] [Related]
16. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses].
Li N; Fan XG; Tang SE; Zhu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582
[TBL] [Abstract][Full Text] [Related]
17. Antimalarial artesunate protects sepsis model mice against heat-killed Escherichia coli challenge by decreasing TLR4, TLR9 mRNA expressions and transcription factor NF-kappa B activation.
Li B; Zhang R; Li J; Zhang L; Ding G; Luo P; He S; Dong Y; Jiang W; Lu Y; Cao H; Zheng J; Zhou H
Int Immunopharmacol; 2008 Mar; 8(3):379-89. PubMed ID: 18279792
[TBL] [Abstract][Full Text] [Related]
18. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A
Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827
[TBL] [Abstract][Full Text] [Related]
19. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do.
Najar HM; Dutz JP
Eur J Immunol; 2007 Aug; 37(8):2242-56. PubMed ID: 17634951
[TBL] [Abstract][Full Text] [Related]
20. Synergistic stimulation of antigen presenting cells via TLR by combining CpG ODN and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants.
Shima F; Uto T; Akagi T; Akashi M
Bioconjug Chem; 2013 Jun; 24(6):926-33. PubMed ID: 23631730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]